FSC Laboratories To Market Cefaclor For Oral Suspension In The U.S.

CHARLOTTE, N.C.--(BUSINESS WIRE)--FSC Therapeutics, LLC, today announced that the Company has entered into a transaction with Yung Shin Pharm. Ind. Co., Ltd. to acquire exclusive U.S. marketing rights for Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, for the treatment of otitis media, lower respiratory infections, pharyngitis and tonsillitis, urinary tract infections and skin and skin structure infections, caused by susceptible organisms. Cefaclor for Oral Suspension will be distributed by FSC Laboratories, Inc., and promoted by its subsidiary, FSC Pediatrics, Inc., to pediatric primary care-focused practitioners across the U.S.

Help employers find you! Check out all the jobs and post your resume.